For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.
“We expect patients to lose anywhere from 5 to 12 per cent of their total body weight,” he adds. However, not all who have diabetes will be prescribed Ozempic, notes Dr Tan. As a first-line ...
Many medications that are commonly referred to as “weight loss drugs” are not actually FDA-approved for this purpose. One of the most popular—Ozempic—is a type 2 diabetes drug that’s often prescribed ...